[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100468825":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":41,"centralContacts":48,"locations":56,"responsibleParty":333,"collaborators":24,"id":335,"slug":24,"hasResults":336,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":336,"sex":342,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":24,"studyType":348,"phases":349,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":77,"whyStopped":24,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":368},{"fullName":5,"class":6},"Centre Oscar Lambret","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Arm - Vincristine + Irinotécan + Témozolomide + Etoposide + Cis-Retinoic acid","EXPERIMENTAL","Metronomic chemotherapy : Vincristine + Irinotécan + Témozolomide + Etoposide + Cis-Retinoic acid",[13,14,15,16,17],"Drug: Vincristine","Drug: Irinotecan","Drug: Temozolomide","Drug: Etoposide","Drug: Cis-Retinoic acid",[19,25,29,33,37],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Vincristine","IV, D1-D22-D43 and D64",[9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Irinotecan","Oral, 5 days\u002Fweek during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)",[9],{"type":20,"name":30,"description":31,"armGroupLabels":32,"otherNames":24},"Temozolomide","Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)",[9],{"type":20,"name":34,"description":35,"armGroupLabels":36,"otherNames":24},"Etoposide","Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)",[9],{"type":20,"name":38,"description":39,"armGroupLabels":40,"otherNames":24},"Cis-Retinoic acid","Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)",[9],[42,45],{"name":43,"affiliation":5,"role":44},"Hélène SUDOUR-BONNANGE, MD","PRINCIPAL_INVESTIGATOR",{"name":46,"affiliation":47,"role":44},"Arnauld VERSCHUUR, MD, PhD","CHU La Timone",[49,54],{"name":50,"role":51,"phone":52,"phoneExt":24,"email":53},"Emilie Heyman - Decoupigny","CONTACT","+33 (0)3 20 29 59 18","promotion@o-lambret.fr",{"name":55,"role":51,"phone":52,"phoneExt":24,"email":53},"Marie Vanseymortier",[57,75,90,105,120,137,152,168,183,198,213,228,243,258,273,288,303,318],{"facility":58,"status":59,"city":60,"state":24,"zip":61,"country":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"CHU Amiens Picardie","NOT_YET_RECRUITING","Amiens","80054","France",{"type":64,"coordinates":65},"Point",[66,67],2.3,49.9,{"lat":67,"lon":66},[70,74],{"name":71,"role":51,"phone":72,"phoneExt":24,"email":73},"Leslie ANDRY, MD","+33 3 22 08 76 44","andry.leslie@chu-amiens.fr",{"name":71,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":76,"status":77,"city":78,"state":24,"zip":24,"country":62,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"CHU de Besancon","RECRUITING","Besançon",{"type":64,"coordinates":80},[81,82],6.01815,47.24878,{"lat":82,"lon":81},[85,89],{"name":86,"role":51,"phone":87,"phoneExt":24,"email":88},"Véronique LAITHIER, MD","0381219182","vlaithier@chu-besancon.fr",{"name":86,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":91,"status":77,"city":92,"state":24,"zip":93,"country":62,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"CHRU de Bordeaux Hôpital des Enfants","Bordeaux","33076",{"type":64,"coordinates":95},[96,97],-0.58046,44.84124,{"lat":97,"lon":96},[100,104],{"name":101,"role":51,"phone":102,"phoneExt":24,"email":103},"Anne NOTZ- CARRERE, MD","+33 5 57 82 04 34","anne.notz-carrere@chu-bordeaux.fr",{"name":101,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":106,"status":77,"city":107,"state":24,"zip":108,"country":62,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"CHU GRENOBLE ALPES - Hôpital COUPLE ENFANT","Grenoble","38043",{"type":64,"coordinates":110},[111,112],5.71479,45.17869,{"lat":112,"lon":111},[115,119],{"name":116,"role":51,"phone":117,"phoneExt":24,"email":118},"Dominique PLANTAZ, MD","+33 4 76 76 59 11","DPlantaz@chu-grenoble.fr",{"name":116,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":5,"status":77,"city":121,"state":24,"zip":122,"country":62,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Lille","59020",{"type":64,"coordinates":124},[125,126],3.05512,50.63391,{"lat":126,"lon":125},[129,132,135,136],{"name":43,"role":51,"phone":130,"phoneExt":24,"email":131},"+33 3 20 29 59 56","h-sudour@o-lambret.fr",{"name":133,"role":51,"phone":130,"phoneExt":24,"email":134},"Cyril LERVAT, MD","c-lervat@o-lambret.fr",{"name":43,"role":44,"phone":24,"phoneExt":24,"email":24},{"name":133,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":138,"status":77,"city":139,"state":24,"zip":140,"country":62,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Centre Léon Bérard","Lyon","69373",{"type":64,"coordinates":142},[143,144],4.84789,45.74906,{"lat":144,"lon":143},[147,151],{"name":148,"role":51,"phone":149,"phoneExt":24,"email":150},"Benoit DUMONT, MD","+33 4 69 16 65 74","Benoit.DUMONT@ihope.fr",{"name":148,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":153,"status":77,"city":154,"state":24,"zip":155,"country":62,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Hôpital pour Enfants \" La Timone \" AP-HM","Marseille","13005",{"type":64,"coordinates":157},[158,159],5.38107,43.29695,{"lat":159,"lon":158},[162,166],{"name":163,"role":51,"phone":164,"phoneExt":24,"email":165},"Arnauld VERSCHUUR, MD","+33 4 91 38 86 21","arnauld.verschuur@ap-hm.fr",{"name":167,"role":44,"phone":24,"phoneExt":24,"email":24},"Arnauld Verschuur, MD",{"facility":169,"status":59,"city":170,"state":24,"zip":171,"country":62,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"CHU de MONTPELLIER - Hôpital Arnaud de Villeneuve","Montpellier","34295",{"type":64,"coordinates":173},[174,175],3.87635,43.61093,{"lat":175,"lon":174},[178,182],{"name":179,"role":51,"phone":180,"phoneExt":24,"email":181},"Stéphanie HAOUY, MD","+33 4 67 33 65 19","s-haouy@chu-montpellier.fr",{"name":179,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":184,"status":77,"city":185,"state":24,"zip":186,"country":62,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"CHU Nantes","Nantes","44093",{"type":64,"coordinates":188},[189,190],-1.55336,47.21725,{"lat":190,"lon":189},[193,197],{"name":194,"role":51,"phone":195,"phoneExt":24,"email":196},"Estelle THEBAUD, MD","+33 2 40 08 36 10","Estelle.THEBAUD@chu-nantes.fr",{"name":194,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":199,"status":77,"city":200,"state":24,"zip":201,"country":62,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"CHU de Nice - Hôpital Archet 2","Nice","06202",{"type":64,"coordinates":203},[204,205],7.26608,43.70313,{"lat":205,"lon":204},[208,212],{"name":209,"role":51,"phone":210,"phoneExt":24,"email":211},"Joy BENADIBA, MD","+33 4 92 03 92 68","benadiba.j@chu-nice.fr",{"name":209,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":214,"status":77,"city":215,"state":24,"zip":216,"country":62,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"Hôpital Armand-TROUSSEAU","Paris","75012",{"type":64,"coordinates":218},[219,220],2.3488,48.85341,{"lat":220,"lon":219},[223,227],{"name":224,"role":51,"phone":225,"phoneExt":24,"email":226},"Marie Dominique TABONE, MD","+33 1 44 73 68 46","marie-dominique.tabone@aphp.fr",{"name":224,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":229,"status":77,"city":230,"state":24,"zip":231,"country":62,"cosmosGeoPoint":232,"geoPoint":236,"contacts":237},"CHU Hôpital Sud","Rennes","35203",{"type":64,"coordinates":233},[234,235],-1.67431,48.11109,{"lat":235,"lon":234},[238,242],{"name":239,"role":51,"phone":240,"phoneExt":24,"email":241},"Jacinthe BONNEAU-LAGACHERIE, MD","+33 2 99 26 59 17","Jacinthe.BONNEAU-LAGACHERIE@chu-rennes.fr",{"name":239,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":244,"status":77,"city":245,"state":24,"zip":246,"country":62,"cosmosGeoPoint":247,"geoPoint":251,"contacts":252},"Chu Rouen","Rouen","76000",{"type":64,"coordinates":248},[249,250],1.09932,49.44313,{"lat":250,"lon":249},[253,257],{"name":254,"role":51,"phone":255,"phoneExt":24,"email":256},"Aude MARIE-CARDINE, MD","+33 2 32 88 81 91","Aude.Marie-Cardine@chu-rouen.fr",{"name":254,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":259,"status":59,"city":260,"state":24,"zip":24,"country":62,"cosmosGeoPoint":261,"geoPoint":265,"contacts":266},"CHU La Réunion","Saint-Denis",{"type":64,"coordinates":262},[263,264],2.35387,48.93564,{"lat":264,"lon":263},[267,271],{"name":268,"role":51,"phone":269,"phoneExt":24,"email":270},"Yves REGUERRE","0262906110","yves.reguerre@chu-reunion.fr",{"name":272,"role":44,"phone":24,"phoneExt":24,"email":24},"Yves REGUERRE, MD",{"facility":274,"status":77,"city":275,"state":24,"zip":276,"country":62,"cosmosGeoPoint":277,"geoPoint":281,"contacts":282},"CHRU Strasbourg - Hôpital de Hautepierre","Strasbourg","67098",{"type":64,"coordinates":278},[279,280],7.74553,48.58392,{"lat":280,"lon":279},[283,287],{"name":284,"role":51,"phone":285,"phoneExt":24,"email":286},"Sarah JANNIER, MD","+33 3 88 12 87 94","sarah.jannier@chru-strasbourg.fr",{"name":284,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":289,"status":77,"city":290,"state":24,"zip":291,"country":62,"cosmosGeoPoint":292,"geoPoint":296,"contacts":297},"CHU Toulouse - Hôpital des Enfants","Toulouse","70034",{"type":64,"coordinates":293},[294,295],1.44367,43.60426,{"lat":295,"lon":294},[298,302],{"name":299,"role":51,"phone":300,"phoneExt":24,"email":301},"Cécile BOULANGER, MD","+33 5 34 55 75 66","boulanger.c@chu-toulouse.fr",{"name":299,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":304,"status":77,"city":305,"state":24,"zip":306,"country":62,"cosmosGeoPoint":307,"geoPoint":311,"contacts":312},"CHRU NANCY - Hôpital d'Enfants","Vandœuvre-lès-Nancy","54500",{"type":64,"coordinates":308},[309,310],6.17114,48.66115,{"lat":310,"lon":309},[313,317],{"name":314,"role":51,"phone":315,"phoneExt":24,"email":316},"Ludovic MANSUY, MD","+33 3 83 15 47 34","lu.mansuy@chru-nancy.fr",{"name":314,"role":44,"phone":24,"phoneExt":24,"email":24},{"facility":319,"status":77,"city":320,"state":24,"zip":321,"country":62,"cosmosGeoPoint":322,"geoPoint":326,"contacts":327},"Gustave ROUSSY","Villejuif","94805",{"type":64,"coordinates":323},[324,325],2.35992,48.7939,{"lat":325,"lon":324},[328,332],{"name":329,"role":51,"phone":330,"phoneExt":24,"email":331},"Claudia PASQUALINI, MD","+33 1 42 11 42 11","Claudia.pasqualini@gustaveroussy.fr",{"name":329,"role":44,"phone":24,"phoneExt":24,"email":24},{"type":334,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100468825",false,"NCT05384821","Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)","Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor","MetroWilms","Inclusion Criteria:\n\n* Patient ≥18 months old and ≤ 17 years old\n* Relapsed or refractory Wilms tumor, histologically proven at diagnosis\n* After at least 2 lines of chemotherapy (conventional or high dose, which may include the trial molecules) or after 1 line for high risk relapse for which there would not be any curative therapy. If 1 line for high risk relapse, the enrolment should be confirmed by coordinators.\n* Radiologically measurable or evaluable disease (visible, target or non-target-lesion on MRI or CT-scan)\n* Performance status: Karnofsky performance status (for patients \\>16 years of age) or Lansky Play score (for patients ≤16 years of age) ≥ 70%.\n* Able to take oral medication or nasal gastric tube or authorized gastrostomy\n* Adequate biological criteria:\n\n  * Neutrophils \\> 1000\u002Fmm3 ; Platelets \\> 75 000\u002Fmm3\n  * Transaminases (ALT\u002F AST) ≤ 3 times ULN (or ≤ 6 times ULN if liver metastasis); total bilirubin ≤ 2 ULN (except in case of Gilbert's disease)\n* Creatinine ≤ 1,5 ULN or clearance ≥ 60 mL\u002F min\u002F 1,73m2 (In case of doubt, to be confirm by assessment of cystatin )\n* Females of childbearing potential must have a negative seric pregnancy test within 7 days prior to initiation of treatment.\n* Sexually active patients must agree to use adequate and appropriate contraception (at least one highly effective contraception or two complementary methods of contraception), 1 month before beginning of treatment while on trial drug and for 7 months after stopping the trial drug for female patients and after 6 months for male patients.\n* Written informed consent from parents\u002Flegal representative, patient, and age-appropriate assent before any trial-specific screening procedures according to national guidelines.\n* Patient covered by the French \"Social Security\" regime\n\nExclusion Criteria:\n\n* Prior history of other cancer within 5 years\n* Chemotherapy or radiotherapy of target lesion within 3 weeks prior to inclusion\n* Target therapy within less than 5 \\* half-life of the substance prior to inclusion\n* Major surgery within 15 days prior to inclusion\n* Presence of any NCI-CTCAE v5 grade ≥ 2 cardiac, hepatic, pulmonary or renal toxicity\n* Severe myelosuppression\n* Severe peripheral neuropathy (grade ≥ 2)\n* Fructose intolerance\n* Inflammatory bowel chronic disease and\u002For intestinal obstruction\n* Patients with demyelinating form of Charcot-Marie-Tooth disease\n* Known active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.\n* Known hypersensitivity to dacarbazine (DTIC), isotretinoin or to any of the trial drugs, trial drug classes, excipients in the formulation\n* Hyperlipidemia and hypervitaminosis A\n* Vaccination with a live attenuated vaccine within 1 month prior to inclusion\n* Pregnant or breastfeeding patients\n* Inability to comply with medical follow-up of the trial (geographical, social or psychological reasons)","ALL","18 Months","17 Years",{"count":346,"type":347},28,"ESTIMATED","INTERVENTIONAL",[350,351],"PHASE1","PHASE2","This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.",[354],"Wilms Tumor",[356,357,354,358],"Multidrug chemotherapy","metronomic chemotherapy","Renal cancer","2026-03-16",{"date":361,"type":362},"2026-03-18","ACTUAL",{"date":364,"type":362},"2022-09-14",{"date":366,"type":347},"2028-10",{"name":5,"class":6},18]